Citations

Clear

815 citation(s) found for "Tang, Yu".

Increased Glycolysis and ATP Production Are Not Prerequisites for Cardiomyocytes Cell Cycle Induction
Zhu, Wuqiang, Tang, Ling , Zhu, Wuqiang

Mayo Clinic

The FASEB Journal | May 3, 2022 | Volume: 36 | Issue: S1 | Pages: No page available

10.1096/fasebj.2022.36.s1.0r777 Get It

Background It has been reported that metabolic switch from fatty acid oxidation to glycolysis is associated with cardiomyocyte cell cycle induction. However, it is unknown if increased glycolysis and ATP production are indispensable for cardiomyocyte cell cycle induction. Here, we aim to address this question. Methods Cell cycle was induced by overexpression of CCND2 gene or treatment of FGF1 (100 ng/mL) and CHIR99021 (5 µM) on human induced pluripotent stem cells‐derived cardiomyocytes (hiPSC‐CMs). Contraction inhibition was induced by treatment of verapamil (0.5 μM). Cell cycle was evaluated by immunostaining using antibodies against cell cycle markers. Real‐time ATP production and mitochondrial oxidative phosphorylation were determined by Seahorse assay. Metabolic profile was assessed by liquid chromatography–mass spectrometry. Results Treatment of FGF1 and CHIR99021 induces cell cycle of hiPSC‐CMs, reduced carbohydrate metabolism and real‐time ATP production from both mitochondria and cytoplasm. Data from RNA Sequencing showed this treatment increased expression of CCND2 and CDK4 and decreased expression of sarcomeric contractile related genes. Overexpression of CCND2 in hiPSC‐CMs also induces cell cycle, increased aerobic glycolysis (Warburg effect) and no change of real‐time ATP production. Inhibition of contraction via treatment of verapamil resulted in reduced overall metabolism and real‐time ATP production. Conclusion Our data suggest that cardiomyocyte cell cycle may be induced without increased glycolysis or real‐time ATP production.
Metabolic Profile in Neonatal Pig Hearts
Li, Pengsheng , Zhu, Wuqiang, Tang, Ling , Zhu, Wuqiang

Mayo Clinic

The FASEB Journal | May 3, 2022 | Volume: 36 | Issue: S1 | Pages: No page available

10.1096/fasebj.2022.36.s1.r5313 Get It

Background Cardiomyocytes in postnatal hearts undergo hypertrophy to adapt to increased blood pressure and volume. The process of cardiomyocyte maturation is associated with a cessation from cell cycle and a series of metabolic switches. Prior research has shown metabolic switches in developing mouse hearts. However, metabolic changes in postnatal pig hearts have not been reported. Methods We evaluated the metabolic profile in pig hearts at postnatal day 1 (P1), day 3 (P3), day 7 (P7), and day 28 (P28) (n=6 each, both males and females; Yorkshire‐Landrace Cross background) using a targeted liquid chromatography tandem mass spectrometry assay. Expression of lactate dehydrogenase isoforms was evaluated by western blotting. Results There is a clear separation of the detected metabolites in P1 versus P28 hearts. Active anabolisms of nucleotide and proteins were observed in P1 hearts when cardiomyocytes retain high cell cycle activity. Abundance of the intermediate metabolites in the pathways of glycolysis was decreased in P28 comparing to P1 hearts, which implicates an overall reduced level of glycolysis. The decreased abundance of intermediates in TCA cycle and increased abundance of lactic acid in P28 hearts suggested that glycolysis rather than glucose oxidation is the main form of glucose metabolism in mature pig hearts. Reduced abundance of GLCN6P was observed in P28 hearts compared to P1 hearts. Increased abundance of hydroxyproline was observed in P1, P3, and P7 hearts compared to P28 heart. Conclusion Postnatal cardiomyocyte maturation is associated with metabolic switch from glucose to fatty acids, active posttranslational protein modification and ECM remodeling.
Abstract 14006: Cardiovascular Health Benefits of Theobromine in Cacao and Chocolate
Hahn, Joshua , Krittanawong, Chayakrit , Virk, Hafeez Ul Hassan , Wang, Zhen, Tang, W.H. Wilson

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.14006 Get It

Introduction: Theobromine is a naturally occurring substance found in cocoa products. Theobromine may have beneficial cardiovascular effects through various mechanisms. We used the NHANES database to analyze associations between theobromine consumption and cardiovascular health outcomes. Methods: The NHANES database represents a nationally representative population which was used to construct the study population from 1996-2016. We assessed multiple demographic factors and compared differences amongst those who consumed various amounts of theobromine to those who did not. The primary outcome measures were hypertension and lipid profiles. Results: Among 42,038 NHANES survey participants, 37569 and 4469 of the participants reported never consuming theobromine and consuming theobromine, respectively. Table 1 demonstrates baseline characteristics of those reporting no theobromine consumption in comparison to the theobromine consuming participants (100-400md/g and 400-850mg/d). Moderate to high amounts of theobromine consumption was observed in participants who were older with higher BMI and more education and were more likely to be tobacco users in comparison to those with no theobromine consumption (all p-values <0.05). Moderate to high theobromine consumption was also observed to be associated with a higher hemoglobin level, higher LDL cholesterol, lower HDL cholesterol, and prevalence of hypertension (all p-values <0.05). Conclusions: We observed that individuals who consumed moderate to high amounts of theobromine had associated improvements in lipid profile parameters as well as reduced blood pressure. Theobromine may represent a complementary non-pharmacologic supplementation to typical lifestyle modifications to improve cardiovascular outcomes. Further prospective studies are needed to better clarify this potential association.
Predictive metabolic networks reveal sex‐ and APOE genotype‐specific metabolic signatures and drivers for precision medicine in Alzheimer's disease
Chang, Rui , Trushina, Eugenia , Zhu, Kuixi , Zaidi, Syed Shujaat Ali , Lau, Branden M, Moein, Sara, He, Qianying, Alamprese, Melissa , Vagnerova, Barbora, Tang, Andrew, Vijayan, Ramachandran , Liu, Yan‐Yun , Saykin, Andrew J. , Young‐Pearse, Tracy L. , Saykin, Andrew J , Trushina, Eugenia , Kueider‐Paisley, Alexandra , Tang, Andrew, Vijayan, Ramachandran, Brinton, Roberta Dı́az , Kaddurah‐Daouk, Rima

Mayo Clinic

Alzheimer's & Dementia | April 28, 2022 | Volume: 19 | Issue: 2 | Pages: 518-531

10.1002/alz.12675 | PMID 35481667 Get It

Abstract Introduction Late‐onset Alzheimer's disease (LOAD) is a complex neurodegenerative disease characterized by multiple progressive stages, glucose metabolic dysregulation, Alzheimer's disease (AD) pathology, and inexorable cognitive decline. Discovery of metabolic profiles unique to sex, apolipoprotein E ( APOE ) genotype, and stage of disease progression could provide critical insights for personalized LOAD medicine. Methods Sex‐ and APOE ‐specific metabolic networks were constructed based on changes in 127 metabolites of 656 serum samples from the Alzheimer's Disease Neuroimaging Initiative cohort. Results Application of an advanced analytical platform identified metabolic drivers and signatures clustered with sex and/or APOE ɛ4, establishing patient‐specific biomarkers predictive of disease state that significantly associated with cognitive function. Presence of the APOE ɛ4 shifts metabolic signatures to a phosphatidylcholine‐focused profile overriding sex‐specific differences in serum metabolites of AD patients. Discussion These findings provide an initial but critical step in developing a diagnostic platform for personalized medicine by integrating metabolomic profiling and cognitive assessments to identify targeted precision therapeutics for AD patient subgroups through computational network modeling.
Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors
He, Zhijian , Deva, Sanjeev , Hung, Tak, Clarke, Katriona, Chao, Tsu‐Yi , Dai, Ming‐Shen , Yeh, Hsien‐Tang , Kramer, Douglas, Kwan, Rudolf, Cutler, David L. , Zhi, Jay, Jackson, Christopher , Segelov, Eva , Wee, Wen , Chan, Wing‐Kai

Mayo Clinic

CPT: Pharmacometrics & Systems Pharmacology | April 26, 2022 | Volume: 11 | Issue: 7 | Pages: 867-879

10.1002/psp4.12799 | PMID 35470967 Get It

AbstractOraxol consists of an oral dosage form of the chemotherapeutic agent paclitaxel administered with a novel P‐glycoprotein inhibitor encequidar methanesulfonate monohydrate (formerly named HM30181A), which allows oral treatment of cancers that would otherwise be treated with intravenous paclitaxel. Here we describe the population pharmacokinetics (popPK) analyses for oral paclitaxel in patients with advanced/metastatic solid tumors to characterize pharmacokinetic (PK) profiles and quantify sources of PK variability. The best fit popPK model for oral paclitaxel, based on data from seven clinical studies (197 patients with advanced/metastatic solid tumors), involves a linear two‐compartment structural model containing first‐order absorption with a short lag time and first‐order elimination as well as a log additive error. In this popPK model, lower population estimates of central volume for Asian patients versus Caucasian patients did not translate into clinical meaningful differences in oral paclitaxel exposure. Age, sex, body weight or surface area, mild hepatic impairment, and mild to moderate renal impairment had no clinically meaningful effects on the systemic exposure of oral paclitaxel. Simulations were performed on clinical therapeutic dose (oral paclitaxel 205 mg/m2 once daily ×3 days per week) to predict exposure of oral paclitaxel and to support treatment benefits observed in a pivotal phase III trial.
Microvascular remodeling and altered angiogenic signaling in human kidneys distal to occlusive atherosclerotic renal artery stenosis
Klomjit, Nattawat , Zhu, Xiangyang , Eirin, Alfonso , Conley, Sabena M., Ferguson, Christopher M. , Jordan, Kyra L., Saadiq, Ishran M. , Grande, Joseph P. , Textor, Stephen C., Lerman, Lilach O. , Pawar, Aditya S. , Kim, Seo Rin , Lerman, Amir , Lerman, Lilach O , Eirin, Alfonso , Klomjit, Nattawat , Puranik, Amrutesh S. , Tang, Hui Jun , Lerman, Amir

Mayo Clinic

Nephrology Dialysis Transplantation | April 19, 2022 | Volume: 37 | Issue: 10 | Pages: 1844-1856

10.1093/ndt/gfac156 | PMID 35451482 Get It

ABSTRACT Background Renal artery stenosis (RAS) is an important cause of chronic kidney disease and secondary hypertension. In animal models, renal ischemia leads to downregulation of growth factor expression and loss of intrarenal microcirculation. However, little is known about the sequelae of large-vessel occlusive disease on the microcirculation within human kidneys. Method This study included five patients who underwent nephrectomy due to renovascular occlusion and seven nonstenotic discarded donor kidneys (four deceased donors). Micro-computed tomography was performed to assess microvascular spatial densities and tortuosity, an index of microvascular immaturity. Renal protein expression, gene expression and histology were studied in vitro using immunoblotting, polymerase chain reaction and staining. Results RAS demonstrated a loss of medium-sized vessels (0.2–0.3 mm) compared with donor kidneys (P = 0.037) and increased microvascular tortuosity. RAS kidneys had greater protein expression of angiopoietin-1, hypoxia-inducible factor-1α and thrombospondin-1 but lower protein expression of vascular endothelial growth factor (VEGF) than donor kidneys. Renal fibrosis, loss of peritubular capillaries (PTCs) and pericyte detachment were greater in RAS, yet they had more newly formed PTCs than donor kidneys. Therefore, our study quantified significant microvascular remodeling in the poststenotic human kidney. RAS induced renal microvascular loss, vascular remodeling and fibrosis. Despite downregulated VEGF, stenotic kidneys upregulated compensatory angiogenic pathways related to angiopoietin-1. Conclusions These observations underscore the nature of human RAS as a microvascular disease distal to main vessel stenosis and support therapeutic strategies directly targeting the poststenotic kidney microcirculation in patients with RAS.
The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
Tang, Hoi Ki Karen, Fung, Chi Yeung, Kumar, Shaji , Siu, Lisa L. P. , Ip, Ho Wan Alvin, Yip, Sze Fai, Lau, Ka Ngai Harry, Lau, Chi Kuen, Leung, Kwan Hung, Kho, B C S, Wong, Howard, Ngai, Cheong , Hwang, Yu Yan, Sim, Joycelyn, Kumar, Shaji K , Chim, Chor Sang , Morgan, Gareth J. , Lee, Harold , Wong, Howard, Hwang, Yu‐Yan , Kwong, Yok‐Lam , Chim, Chor Sang

Mayo Clinic

Therapeutic Advances in Hematology | April 18, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/20406207221082043 | PMID 35465644 Get It

Introduction: Bortezomib has been reported to favourably impact the outcomes of t(4;14) and del(17p) in multiple myeloma (MM), but its impact on gain 1q (+1q) is unknown. Methods: To address this, 250 patients treated with bortezomib-based induction were analysed. All myeloma samples had fluorescence in situ hybridization (FISH) performed on CD138-sorted bone marrow aspirate, and plasma cells were analysed using DNA probes specific for the following chromosomal aberrations: del(13q14), del(17p), t(14;16), t(4;14), and +1q. Presence of +1q was defined as the presence of at least three copies of 1q21 at the cut off level of 20% of bone marrow plasma cells. Results: +1q identified in 167 (66.8%) and associated with t(4;14) and high lactate dehydrogenase (LDH). +1q was not associated with response rate but shorter event-free survival (EFS) (median EFS 35 vs 55 months, p = 0.05) and overall survival (OS) (median OS 74 vs 168 months, p = 0.00025). Copy number and clone size did not impact survival. Multivariate analysis showed +1q was an independent adverse factor for OS together with International Staging System (ISS)3, high LDH, del(17p) and t(4;14). When a risk score of 1 was assigned to each independent adverse factor, OS was shortened incrementally by a risk score from 0 to 4. Post-relapse/progression survival was inferior in those with +1q (median 60 vs 118 months, p = 0.000316). Autologous stem cell transplantation (ASCT) improved OS for those with +1q (median OS 96 vs 49 months, p = 0.000069). Conclusion: +1q is an adverse factor for OS in MM uniformly treated with bortezomib-based induction but was partially mitigated by ASCT. A risk scoring system comprising +1q, LDH, high-risk FISH, and ISS is a potential tool for risk stratification in MM.
Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
Tang, Yi-Hui , Lin, Guan-Jie, Ma, Yu‐Bin , Desiderio, Jacopo , Li, Ping , Lü, Jun, Cao, Long‐Long, Zheng, Chao‐Hui , Parisi, Amilcare , Truty, Mark J. , Huang, Chang‐Ming , Lin, Jian‐Xian , Xie, Jian‐Wei , Wang, Jia-Bin , Chen, Qi‐Yue , Lin, Mi , Tu, Ru‐Hong

Mayo Clinic

JAMA Network Open | April 1, 2022 | Volume: 5 | Issue: 4 | Pages: e225557

10.1001/jamanetworkopen.2022.5557 | PMID 35363268 Get It

Reverberation clutter signal suppression in ultrasound attenuation estimation using wavelet-based robust principal component analysis
Lok, U‐Wai , Huang, Chengwu , Tang, Shanshan , Zhou, Chenyun , Watt, Kymberly D., Callstrom, Matthew R. , Trzasko, Joshua D. , Chen, Shigao , Gong, Ping , Huang, Chengwu , Yang, Lulu, Callstrom, Matthew, Lok, U-Wai , Gong, Ping , Yang, Lulu

Mayo Clinic

Physics in Medicine & Biology | March 31, 2022 | Volume: 67 | Issue: 9 | Pages: 095018

10.1088/1361-6560/ac62fd | PMID 35358950 Get It

Abstract Objective . Ultrasound attenuation coefficient estimation (ACE) has diagnostic potential for clinical applications such as quantifying fat content in the liver. Previously, we have proposed a system-independent ACE technique based on spectral normalization of different frequencies, called the reference frequency method (RFM). This technique does not require a well-calibrated reference phantom for normalization. However, this method may be vulnerable to severe reverberation clutter introduced by the body wall. The clutter superimposed on liver echoes may bias the estimation. Approach . We proposed to use robust principal component analysis, combined with wavelet-based sparsity promotion, to suppress the severe reverberation clutters. The capability to mitigate the reverberation clutters was validated through phantom and in vivo studies. Main Results . In the phantom studies with added reverberation clutters, higher normalized cross-correlation and smaller mean absolute errors were attained as compared to RFM results without the proposed method, demonstrating the capability to reconstruct tissue signals from reverberations. In a pilot patient study, the correlation between ACE and proton density fat fraction (PDFF), a measurement of liver fat by MRI as a reference standard, was investigated. The proposed method showed an improvement of the correlation (coefficient of determination, R = 0.82) as compared with the counterpart without the proposed method ( R = 0.69). Significance : The proposed method showed the feasibility of suppressing the reverberation clutters, providing an important basis for the development of a robust ACE with large reverberation clutters.
Soluble LILRA3 is aberrantly expressed in antiphospholipid syndrome (APS) and is a potential marker of thrombotic APS
Liu, Hongjiang , Li, Chun , Guo, Yixue , Tang, Yundi, Chen, Chen , Zhao, Zhen , Hoy, Claire K., Yalavarthi, Srilakshmi , Figueroa‐Parra, Gabriel , Zuo, Yu , Guo, Jianping , Guo, Yixue , Figueroa-Parra, Gabriel , Duarte-García, Alí , Zuo, Yu , Shi, Hui , Duarte‐García, Alí , Li, Zhanguo , Knight, Jason S

Mayo Clinic

Rheumatology | March 23, 2022 | Volume: 61 | Issue: 12 | Pages: 4962-4974

10.1093/rheumatology/keac192 | PMID 35325077 Get It

Abstract Objective Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors. Our previous study reported LILRA3 transcripts were markedly upregulated in neutrophils from patients with APS. We undertook this study to investigate clinical implications of LILRA3 in APS and its potential role in APS-associated thrombosis. Methods Two independent cohorts were studied. The first consisted of 294 APS patients, 48 asymptomatic aPL carriers and 150 healthy controls (HCs) from Peking University People’s Hospital. The second included 99 APS patients, 25 aPL carriers and 40 HCs from United States APS centres. Serum or plasma concentrations of LILRA3 and MPO-DNA complexes were measured. Additionally, 35 patients with thrombotic APS (tAPS) were evaluated to determine potential effects of immunosuppressive therapy on serum concentrations of LILRA3 and MPO-DNA complexes. Results Both positivity and serum concentration of LILRA3 were significantly increased in APS patients, especially in those with tAPS. LILRA3-positive tAPS patients displayed more severe thrombotic manifestations. Serum LILRA3 was positively correlated with MPO-DNA complexes in LILRA3-positive tAPS. After immunosuppressive treatment, LILRA3 and MPO-DNA complexes were consistently decreased in tAPS patients. Key findings from the Peking cohort were confirmed in the United States cohort. Conclusion Our study provides first evidence that LILRA3 is aberrantly expressed in APS, especially in patients with tAPS. Serum LILRA3 correlated with MPO-DNA complexes, and the two indices were consistently decreased in tAPS patients after treatment. LILRA3 may play a role in thrombosis of APS and may serve as a biomarker and/or therapeutic target in tAPS.